Hi-Clearance (1788) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 杏昌

Hi-Clearance (1788) reported revenue of NT$378.8 million for Oct 2026, +1.4% year on year and -8.7% from the previous month. Revenue for Jan–Oct 2026 was NT$3.79 billion (+6.5% year on year).

Year-on-year revenue growth: 17 months in a row. →

In Oct 2026, it ranked No. 23 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$336.5 million24/10Nov 2024 NT$301.7 millionDec 2024 NT$363.7 millionJan 2025 NT$369.9 millionFeb 2025 NT$310.9 million25/02Mar 2025 NT$369.8 millionApr 2025 NT$360.4 millionMay 2025 NT$330.9 millionJun 2025 NT$378.8 million25/06Jul 2025 NT$353 millionAug 2025 NT$351.7 millionSep 2025 NT$361 millionOct 2025 NT$373.4 million25/10Nov 2025 NT$326.3 millionDec 2025 NT$392.3 millionJan 2026 NT$420.9 millionFeb 2026 NT$332.3 million26/02Mar 2026 NT$392 millionApr 2026 NT$369.6 millionMay 2026 NT$345.2 millionJun 2026 NT$392.8 million26/06Jul 2026 NT$362.9 millionAug 2026 NT$383.2 millionSep 2026 NT$414.8 millionOct 2026 NT$378.8 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$378.8 million+1.4%-8.7%
Sep 2026NT$414.8 million+14.9%+8.3%
Aug 2026NT$383.2 million+8.9%+5.6%
Jul 2026NT$362.9 million+2.8%-7.6%
Jun 2026NT$392.8 million+3.7%+13.8%
May 2026NT$345.2 million+4.3%-6.6%
Apr 2026NT$369.6 million+2.6%-5.7%
Mar 2026NT$392 million+6.0%+18.0%
Feb 2026NT$332.3 million+6.9%-21.1%
Jan 2026NT$420.9 million+13.8%+7.3%
Dec 2025NT$392.3 million+7.9%+20.2%
Nov 2025NT$326.3 million+8.1%-12.6%
Oct 2025NT$373.4 million+11.0%+3.5%
Sep 2025NT$361 million+6.7%+2.6%
Aug 2025NT$351.7 million+2.1%-0.4%
Jul 2025NT$353 million+8.2%-6.8%
Jun 2025NT$378.8 million+7.5%+14.5%
May 2025NT$330.9 million-1.2%-8.2%
Apr 2025NT$360.4 million-12.1%-2.5%
Mar 2025NT$369.8 million+16.1%+18.9%
Feb 2025NT$310.9 million+11.2%-15.9%
Jan 2025NT$369.9 million+0.8%+1.7%
Dec 2024NT$363.7 million+4.1%+20.5%
Nov 2024NT$301.7 million-5.1%-10.3%
Oct 2024NT$336.5 million+6.9%-0.5%

Jan–Oct 2026 cumulative: NT$3.79 billion (+6.5% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: Hi-Clearance vs PEC / Hi-Clearance vs Lotus Pharm / Hi-Clearance vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16